This is the second biosimilar now available in the US market under the Teva and Alvotech strategic partnership. The FDA has provisionally determined that SELARSDI (ustekinumab-aekn) will be interchangeable with the reference biologic Stelara (ustekinumab), following the expiration of exclusivity for the first interchangeable biosimilar, on April 30, 2025.

“The US launch of SELARSDI is an important step for our partnership and reaffirms a joint commitment to providing more affordable treatment options for US patients,” says Anil Okay, Chief Commercial Officer for Alvotech. “Alvotech’s fully integrated approach to development and manufacturing, coupled with our focus on biosimilars, enables us to continue expanding a portfolio of high-quality biologics and contribute meaningfully to lowering healthcare costs world-wide.”

Learn more about Alvotech’s journey in our latest issue of NLS magazine.

subscribe here!

Ustekinumab

Ustekinumab is a human monoclonal antibody (mAb) that selectively targets the p40 protein, a component common to both interleukin (IL)-12 and IL-23 cytokines, which play crucial roles in treating immune-mediated diseases like psoriasis and psoriatic arthritis, and inflammatory diseases like Crohn’s disease and ulcerative colitis. Alvotech developed and produces SELARSDI using Sp2/0 cells and a continuous perfusion process, which are the same type of host cell line and process used in the production of Stelara.

Related article

Biosimilars: Opportunities & Challenges

The development and use of biosimilars continues to grow in the Nordic countries, as well as the rest of Europe, and experts are excited about their potential. But there is a thicket of legal issues and regulations that companies have to navigate to get their drugs to the market. A biosimilar is almost identical to […]

The Teva-Alvotech collaboration

In August 2020, Teva and Alvotech entered into a strategic partnership for the exclusive commercialization of five Alvotech biosimilar product candidates, and in July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products.

Alvotech manages development and manufacturing, while Teva is responsible for the exclusive commercialization in the US, leveraging the experience and extensive sales and marketing infrastructure from Teva.

Two biosimilars developed under the partnership have been given US FDA approval: most recently, SELARSDI in April 2024; and in February 2024, SIMLANDI (adalimumab-ryvk), the first high-concentration, citrate-free interchangeable biosimilar to Humira, which was launched in the US in May 2024.